Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion-Like Disorder?

Movement Disorders

Volumn 28, Issue 1, 2013, Pages 31-40

  Olanow, C Warren ^a   Brundin, Patrik ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

sheet formation; Lewy like pathology; Misfolded synuclein; Prions; Toxic oligomers

Indexed keywords

ALPHA SYNUCLEIN; OLIGOMER; PRION PROTEIN;

AMYLOID PLAQUE; BETA SHEET; BRAIN TRANSPLANTATION; CONFORMATIONAL TRANSITION; DOPAMINERGIC NERVE CELL; HUMAN; IMMUNIZATION; LEWY BODY; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; POINT MUTATION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LEWY BODIES; MUTATION; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PRION DISEASES; PROTEIN STRUCTURE, SECONDARY;

EID: 84873458538     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25373     Document Type: Review

References (70)

1. Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 2012;336:1511-1513.
2. Prusiner SB. Shattuck lecture-neurodegenerative diseases and prions. N Engl J Med 2001;344:1516-1526.
3. Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998;95:13363-13383.
4. Lewy FH. Paralysis agitans. I. Pathologische Anatomie. In: Lewandowsky M, ed. Handbuch de Neurologie. Berlin: Springer; 1912:920-933.
5. Tretiakoff C. Contribution a l'etude de l'anatomie pathologique du locus niger de Soemmering avec quelques deductions relatives a la pathogenie des troubles du tonus musculaires et de la maladie de Parkinson. Rev Neurol (Paris) 1921;28:592-600.
6. Olanow CW, Perl DP, DeMartino GN, McNaught K. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 2004;3:496-503.
7. Milber JM, Noorigian JV, Morley JF, Petrovitch H, White L, Ross GW, Duda JE. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology 2012;79:2307-2314.
8. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
9. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840.
10. Chartier-Harlin MC, Kacherus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004;364:1167-1169.
11. Ibanez P, Bonnet AM, Debarges B, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004;364:1169-1171.
12. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease [serial online]. Science 2003;302:841.
13. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009;41:1303-1307.
14. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009;41:1308-1312.
15. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000;287:1265-1269.
16. Kirik D, Bjorklund A. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci 2003;26:386-392.
17. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2012;27:8-30.
18. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
19. Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 2008;64:485-491.
20. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
21. Lindvall O, Sawle G, Widner H, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994;35:172-180.
22. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathologic evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332:1118-1124.
23. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Parkinson's disease pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008;14:504-506.
24. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008;14:501-503.
25. Kurowska Z, Englund E, Widner H, Lindvall O, Li J-Y, Brudin Pl. Signs of degeneration in 12-22-year old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease. J Parkinsons Dis 2011;1:83-92.
26. Olanow CW, Prusiner SB. Is Parkinson's disease a prion disorder. Proc Natl Acad Sci U S A 2009;106:12571-12572.
27. Angot E, Steiner JA, Hansen C, Li JY, Brundin P. Are synucleinopathies prion-like disorders? Lancet Neurol 2010;9:1128-1138.
28. Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci 2008;9:741-745.
29. Lee H-J, Patel S, Lee S-J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005;25:6016-6024.
30. Lee H-J, Suk JE, Bae EJ, Lee JH, Paik SR, Lee S-J. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol 2008;40:1835-1849.
31. Desplats P, Lee HJ, Bae EJ, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 2009;106:13010-13015.
32. Hansen C, Angot E, Bergstrom A-L, et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011;121:715-725.
33. Kordower JH, Dodiya HB, Kordower AM, et al. Transfer of host-derived α synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis 2011;43:552-557.
34. Luk KC, Song C, O'Brien P, et al. Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. PNAS 2009;106:20051-20056.
35. Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011;72:57-71.
36. Freundt EC, Maynard N, Clancy EK, et al. Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport. Ann Neurol. 2012;72:517-524.
37. Mougenot AL, Nicot S, Bencsik A, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 2012;33:2225-2228.
38. Luk KC, Kehm K, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM-Y. Pathological a-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012;338:949-953.
39. Angot E, Steiner JA, Lema Tome CM, Ekstrom P, Mattsson B, Bjorklund A, Brundin P. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo [serial online]. PLoS One 2012;7:e39465.
40. Emmanouilidou E, Melachroinou K, Roumeliotis T, et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 2010;30:6838-6851.
41. Danzer KM, Kranich LR, Ruf WP, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers [serial online]. Mol Neurodegener 2012;7:42.
42. Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ, Cooper JM. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis 2011;42:360-367.
43. Cremades N, Cohen SI, Deas E, et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 2012;149:1048-1059.
44. Bartels T, Choi JG, Selkoe DJ. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011;477:107-110.
45. Norris EH, Giasson BI, Lee VM. Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol. 2004;60:17-54.
46. Chandra S, Fornai F, Kwon HB, et al. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A 2004;101:14966-14971.
47. Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 2004;24:1888-1896.
48. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem 2008;283:23542-23556.
49. Liu CW, Corboy MJ, DeMartino GN, Thomas PJ. Endoproteolytic activity of the proteasome. Science 2003;299:408-411.
50. Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson's disease. J Biol Chem 2005;280:22670-22678.
51. Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian MM. Degradation of alpha-synuclein by proteasome. J Biol Chem 1999;274:33855-33858.
52. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, Caballero C, Ferrer I, Obeso JA, Schapira AH. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol. 2010;67:1464-1472.
53. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2001;2:589-594.
54. McNaught KS, Mytilineou C, Jnobaptiste R, Yabut J, Shashidharan P, Jennert P, Olanow CW. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 2002;81:301-306.
55. Tanaka Y, Engelender S, Igarashi S, et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 2001;10:919-926.
56. Snyder H, Mensah K, Theisler C, et al. Aggregated and monomeric alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. J Biol Chem 2003;278:11753-11759.
57. Martinez-Vicente M, Talloczy Z, Kaushik S, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008;118:777-788.
58. Cuervo AM, Stefanis L, Fredenburg R, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004;305:1292-1295.
59. Olanow CW, McNaught K. Parkinson's disease, proteins, and prions: milestones. Mov Disord 2011;26:1056-1071.
60. Chu Y, Dodiya1 H, Aebischer P, et al. Alterations in lysosomal and proteasomal markers in Parkinsons disease: relationship to alpha synuclein inclusions. Neurobiol Dis 2009;35:385-398.
61. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57:456-462.
62. Shannon KM, Keshavarzian A, Dodiya HB, et al. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord 2012;27:716-719.
63. Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice [serial online]. PLoS One 2010;5(1):e8762.
64. Pan-Montojo F, Schwarz M, Winkler C, et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice [serial online]. Sci Rep 2012;2:898.
65. Lee HJ, Suk JE, Lee KW, Park SH, Blumbergs PC, Gai WP, Lee SJ. Transmission of synucleinopathies in the enteric nervous system of A53T alpha-synuclein transgenic mice. Exp Neurobiol 2011;20:181-188.
66. Xilouri M, Brekk OR, Stefanis L. Alpha-synuclein and protein degradation systems: a reciprocal relationship [published online ahead of print]. Mol Neurobiol 2012.
67. Chu Y, Kordower JH. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol Dis 2007;25:134-149.
68. Fauvet B, Fares MB, Samuel F, Dikiy I, Tandon A, Eliezer D, Lashuel HA. Characterization of semisynthetic and naturally Nα-acetylated α-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of α-synuclein. J Biol Chem 2012;287:28243-28262.
69. Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005;46:857-868.
70. Bae EJ, Lee HJ, Rockenstein E, et al. Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 2012;32:13454-13469.